Immunomedics Announces Results From Single-Dose Escalation Study of Y-90-Clivatuzumab Tetraxetan in Advanced Pancreatic Cancer Published

Immunomedics, Inc. IMMU today announced that a single dose of clivatuzumab tetraxetan labeled with the potent therapeutic radioisotope, yttrium-90, produced transient partial responses in some patients with advanced pancreatic cancer and the treatment was well tolerated with manageable hematological toxicity at the maximum tolerated 90Y dose. Results from this Phase I study were published online in Clinical Cancer Research by S.A. Gulec, S.J. Cohen, K.L. Pennington, L.S. Zuckier, R.J. Hauke, H. Horne, W.A. Wegener, N. Teoh, D.V. Gold, R.M. Sharkey and D.M. Goldenberg in an article entitled "Treatment of advanced pancreatic carcinoma with 90Y-clivatuzumab tetraxetan: A Phase I single-dose escalation trial."